• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Mallinckrodt agent ready for market

Article

The first nonionic x-ray contrast agent developed in the U.S. was approved for market by the Food andDrug Administration earlier this month. Optiray, a low-osmolalitynonionic contrast agent manufactured by Mallinckrodt, should reachthe market this

The first nonionic x-ray contrast agent developed in the U.S. was approved for market by the Food andDrug Administration earlier this month. Optiray, a low-osmolalitynonionic contrast agent manufactured by Mallinckrodt, should reachthe market this spring, after the company initiates the new productionprocess. The agent, whose chemical name is ioversol, will be soldinitially for computed tomography, angiography, and urographyapplications, a Mallinckrodt spokesperson said.

Mallinckrodt will market Optiray along with Hexabrix, a low-osmolalityionic contrast agent developed by the French pharmaceutical companyGuerbet. Hexabrix has been on the U.S. market for three years.Omnipaque, a nonionic agent developed by Nycomed of Oslo, Norway,is marketed by Kodak's Winthrop Pharmaceuticals in the U.S.

"The market for contrast media is growing rapidly andan increasing portion of it is shifting to new-generation, low-osmolalityproducts, both nonionic and ionic," said Carl Holman, presidentof Mallinckrodt Medical.

The high cost of these new radiographic contrast agents hasrestrained the market. Mallinckrodt hopes to provide its own nonioniccontrast agent at a lower price than European imports, therebystimulating clinical demand (SCAN 2/17/88). The price of Optiray,however, has not been announced.

Mallinckrodt estimates the current U.S. market for x-ray contrastmedia at $500 million per year and forecasts that sales will reach$1 billion by 1993. U.S. sales constitute about half of the worldwidemarket.

The relatively speedy approval for Optiray was welcomed byMallinckrodt. It had filed for approval with the FDA in June 1987.The most optimistic company projection for the final market go-aheadwas "sometime in 1989."

"Despite increasing demand on limited resources, the FDAprovided a timely review of Optiray, which was a large and complicatednew drug application," said Dr. Edward Aten, vice presidentfor medical affairs.

Related Videos
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Reimbursement Challenges in Radiology: An Interview with Richard Heller, MD
Nina Kottler, MD, MS
The Executive Order on AI: Promising Development for Radiology or ‘HIPAA for AI’?
Related Content
© 2024 MJH Life Sciences

All rights reserved.